STOKE THERAPEUTICS INC's ticker is STOK and the CUSIP is 86150R107. A total of 95 filers reported holding STOKE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.14 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $171,503 | -32.5% | 18,581 | -6.1% | 0.00% | – |
| Q3 2022 | $254,000 | -8.6% | 19,798 | -5.9% | 0.00% | – |
| Q2 2022 | $278,000 | -4.8% | 21,031 | +4.0% | 0.00% | – |
| Q1 2022 | $292,000 | -81.6% | 20,224 | -69.4% | 0.00% | -100.0% |
| Q4 2021 | $1,588,000 | +16.7% | 66,171 | +23.7% | 0.00% | 0.0% |
| Q3 2021 | $1,361,000 | -30.8% | 53,482 | -8.5% | 0.00% | -50.0% |
| Q2 2021 | $1,967,000 | -18.1% | 58,438 | -5.5% | 0.00% | 0.0% |
| Q1 2021 | $2,403,000 | -49.6% | 61,859 | -19.6% | 0.00% | -60.0% |
| Q4 2020 | $4,764,000 | +110.5% | 76,928 | +13.8% | 0.01% | +66.7% |
| Q3 2020 | $2,263,000 | +22.9% | 67,576 | -12.5% | 0.00% | +50.0% |
| Q2 2020 | $1,841,000 | -80.2% | 77,262 | -80.9% | 0.00% | -75.0% |
| Q1 2020 | $9,278,000 | +82.4% | 405,126 | +125.5% | 0.01% | +33.3% |
| Q4 2019 | $5,088,000 | +5957.1% | 179,648 | +4491.1% | 0.01% | – |
| Q3 2019 | $84,000 | +15.1% | 3,913 | +56.5% | 0.00% | – |
| Q2 2019 | $73,000 | – | 2,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ATP Life Science Ventures, L.P. | 16,786,713 | $475,340,000 | 79.82% |
| RTW INVESTMENTS, LP | 3,544,248 | $100,373,000 | 3.79% |
| Cormorant Asset Management, LP | 1,788,643 | $50,654,000 | 2.02% |
| RA Capital Management | 1,119,963 | $31,717,000 | 0.96% |
| Redmile Group, LLC | 1,020,778 | $28,908,000 | 0.69% |
| SPHERA FUNDS MANAGEMENT LTD. | 256,380 | $7,261,000 | 0.60% |
| GILDER GAGNON HOWE & CO LLC | 1,826,890 | $51,738,000 | 0.54% |
| Perceptive Advisors | 671,978 | $19,030,000 | 0.38% |
| Casdin Capital, LLC | 130,000 | $3,682,000 | 0.34% |
| Granite Point Capital Management, L.P. | 13,200 | $374,000 | 0.06% |